Lantern Pharma wins USPTO allowance for LP-184 solid tumor patent

The notice of allowance covers biomarker-guided treatment with LP-184, also known as Zirdafulven, across multiple solid tumor cancers.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.